The economics of smoking and cardiovascular disease

Progress in Cardiovascular Diseases

Volumn 46, Issue 1, 2003, Pages 39-78

  Lightwood, James ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ECONOMIC ASPECT; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; MEDICARE; PREVALENCE; REVIEW; SMOKING CESSATION; SMOKING HABIT; UNITED STATES;

EID: 0042467762     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0033-0620(03)00077-X     Document Type: Article

References (217)

1. National Center for Health Statistics: Health, United States, 2002 With Chartbook on Trends in the Health of Americans. Hyattsville, MD, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2002
2. Annual smoking-attributable mortality, years of potential life lost, and economic costs - United States, 1995-1999. MMWR Morb Mortal Wkly Rep 51:300-303, 2002
3. Gruber J: The economics of tobacco regulation. Only the costs that smokers impose on others justify a mandate for government action. Health Aff (Millwood) 21:146-162, 2002
4. Laux FL: Addiction as a market failure: Using rational addiction results to justify tobacco regulation. J Health Econ 19:421-437, 2000
5. Collins DJ, Lapsley HM: Estimating the economic costs of drug abuse in Australia. National Campaign Against Drug Abuse (Australia). Monograph no. 15. Canberra, Australian Govt. Publishing Service, 1991, p 118
6. Collins DJ, Lapsley HM: The social costs of drug abuse in Australia, in 1988 and 1992. National Drug Strategy. Monograph no. 30. Canberra, Australian Govt. Publishing Service for the Commonwealth Department of Human Services and Health, 1996, p 74
7. Warner KE, Fulton GA: The economic implications of tobacco product sales in a nontobacco state. JAMA 271:771-776, 1994
8. Warner KE, Fulton GA, Nicolas P, et al: Employment implications of declining tobacco product sales for the regional economies of the United States. JAMA 275:1241-1246, 1996
9. Warner KE: The economics of tobacco: Myths and realities. Tob Control 9:78-89, 2000
10. Warner KE, Hodgson TA, Carroll CE: Medical costs of smoking in the United States: Estimates, their validity, and their implications. Tob Control 8:290-300, 1999
11. Lightwood J, Collins D, Lapsley H, et al: Estimating the cost of tobacco use, in Jha P, Chaloupka FJ (eds): Tobacco Control in Developing Countries. Oxford, Oxford University Press, pp 63-103, 2000
12. Max W: The financial impact of smoking on health-related costs: A review of the literature. Am J Health Promot 15:321-331, 2001
13. Hodgson TA, Cohen AJ: Medical care expenditures for selected circulatory diseases: Opportunities for reducing national health expenditures. Med Care 37:994-1012, 1999
14. Druss BG, Marcus SC, Olfson M, et al: The most expensive medical conditions in America. Health Aff (Millwood) 21:105-111, 2002
15. Druss BG, Marcus SC, Olfson M, et al: Comparing the national economic burden of five chronic conditions. Health Aff (Millwood) 20:233-241, 2001
16. Ray GT, Collin F, Lieu T, et al: The cost of health conditions in a health maintenance organization. Med Care Res Rev 57:92-109, 2000
17. Dobkin B: The economic impact of stroke. Neurology 45(suppl 1):S6-S9, 1995
18. Taylor TN: The medical economics of stroke. Drugs 54(suppl 3):51-8, 1997
19. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause-2020: Global Burden of Disease Study. Lancet 349:1498-1504, 1990
20. Vorster HH: The emergence of cardiovascular disease during urbanisation of Africans. Public Health Nutr 5:239-243, 2002
21. Weinstein MC, Coxson PC, Williams LW, et al: Forecasting coronary heart disease incidence, mortality, and cost: The Coronary Heart Disease Policy Model. Am J Public Health 77:1417-1426, 1987
22. Goldman L, Weinstein MC, Williams LW: Relative impact of targeted versus populationwide cholesterol interventions on the incidence of coronary heart disease. Projections of the Coronary Heart Disease Policy Model. Circulation 80:254-260, 1989
23. Edelson JT, Weinstein MC, et al: Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 263:407-413, 1990
24. Tsevat J, Weinstein MC, Williams LW, et al: Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 83:1194-1201, 1991
25. Tosteson AN, Weinstein MC, Williams LW, et al: Long-term impact of smoking cessation on the incidence of coronary heart disease. Am J Public Health 80:1481-1486, 1990
26. Goldman L, Phillips KA, Coxson P, et al: The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. J Am Coll Cardiol 38:1012-1017, 2001
27. United States Office on Smoking and Health and United States, Surgeon-General's Office: The Health Consequences of Smoking: Cardiovascular Disease: A Report of the Surgeon General, 1983. Rockville, MD. Washington, DC, U.S. Department of Health and Human Services Public Health Service Office on Smoking and Health, 1983, pp xvii, 384
28. Kleinbaum DG, Morgenstern H, Kupper LL: Epidemiologic research: Principles and quantitative methods. New York, Van Nostrand Reinhold, 1982, pp xix, 529
29. Rothman KJ, Greenland S: Modern epidemiology. 2nd ed. Philadelphia, PA, Lippincott-Raven, 1998, pp xiii, 737
30. Eide GE, Gefeller O: Sequential and average attributable fractions as aids in the selection of preventive strategies. J Clin Epidemiol 48:645-655, 1995
31. Luce BR, Schweitzer SO: Smoking and alcohol abuse: A comparison of their economic consequences. N Engl J Med 298:569-571, 1978
32. Office of Technology Assessment, Smoking Related Deaths and Financial Costs: OTA Staff Memorandum. Washington DC: Health Program, U.S. Congress, 1985
33. Rice DP, Hodgson TA, Sinsheimer P, et al: The economic costs of the health effects of smoking, 1984. Milbank Q 64:489-547, 1986
34. Centers for Disease Control and Prevention, Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAMMEC): Adult SAMMEC and Maternal and Child Health (MCH) SAMMEC software, 2002. Accessed: March 21 2003. Available: http://www.cdc.gov/tobacco/sammec
35. Miller VP, Ernst C, Collin F: Smoking-attributable medical care costs in the USA. Soc Sci Med 48:375-391, 1999
36. Thomas AR, Hedberg K, Fleming DW: Comparison of physician based reporting of tobacco attributable deaths and computer derived estimates of smoking attributable deaths, Oregon, to 1996. Tob Control 10:161-164, 1989
37. Jin SG, Lu BY, Yan DY, et al: An evaluation on smoking-induced health costs in China (1988-1989). Biomed Environ Sci 8:342-349, 1995
38. Ruff LK, Volmer T, Nowak D, et al: The economic impact of smoking in Germany. Eur Respir J 16:385-390, 2000
39. Farley TM, Meirik O, Chang CL, et al: Combined oral contraceptives, smoking, and cardiovascular risk. J Epidemiol Community Health 52;775-785, 1998
40. Puchmayer V: Smoking as a risk factor for the development of arterial occlusive disease. Acta Univ Carol Med Monogr 105:1-134, 1984
41. Gorelick PB, Erkinjuntti T, Hofman A, et al: Prevention of vascular dementia. Alzheimer Dis Assoc Disord 13(suppl 3):S131-S139, 1999
42. Gillings DB: Pentoxifylline and intermittent claudication: Review of clinical trials and cost-effectiveness analyses. J Cardiovasc Pharmacol 25(suppl 2):S44-S50, 1995
43. Lederle F, Johnson GR, Wilson SE, et al: Prevalence and associations of abdominal aortic aneurysm detected through screening. Ann Intern Med 126:441-449, 1997
44. U.K. Small Aneurysm Trial Participants, Brown L, Powell J: Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. Ann Surg 230:289-297, 1999
45. Chang M, Hahn RA, Teusch SM, et al: Multiple risk factors and population attributable risk for ischemic heart disease mortality in the United States, 1971-1992. J Clin Epidemiol 54:634-644, 2001
46. Gillum RF, Mussolino ME, Madans JH: Coronary heart disease risk factors and attributable risks in African-American women and men: NHANES I epidemiologic follow-up study. Am J Public Health 88:913-917, 1998
47. Haapanen-Niemi N, Vuori I, Pasanen M: Public health burden of coronary heart disease risk factors among middle-aged and elderly men. Prev Med 28:343-348, 1999
48. Nakayama T, Date C, Yokoyama T, et al: Population attributable fraction of stroke incidence in middle-aged and elderly people: Contributions of hypertension, smoking and atrial fibrillation. Neuroepidemiology 19:217-226, 2000
49. Malarcher AM, Schulman J, Epstein LA, et al: Methodological issues in estimating smoking-attributable mortality in the United States. Am J Epidemiol 152:573-584, 2000
50. Sturmans F, Mulder PG, Valkenburg HA: Estimation of the possible effect of interventive measures in the area of ischemic heart diseases by the attributable risk percentage. Am J Epidemiol 105:281-289, 1977
51. Thun MJ, Apicella LF, Henley SJ: Smoking vs other risk factors as the cause of smoking-attributable deaths: Confounding in the courtroom. JAMA 284:706-712, 2000
52. English D, Holman CDJ, Milne E, et al: The Quantification of Drug Caused Morbidity and Mortality in Australia, 1995. Canberra, Commonwealth Department of Human Services and Health, 1995
53. Diverse Populations Collaborative Group: Prediction of mortality from coronary heart disease among diverse populations: Is there a common predictive function? Heart 88:222-228, 2002
54. Chambless LE, Dobson AJ, Patterson CC, et al: On the use of a logistic risk score in predicting risk of coronary heart disease. Stat Med 9:385-396, 1990
55. Neaton JD, Wentworth D: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Am Heart J 152:56-64, 1992
56. Willett WC, Green A, Stampfer MJ, et al: Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 317:1303-1309, 1987
57. Leffondre K, Abrahammowicz M, Siemżatycki J, et al: Modeling smoking history: A comparison of different approaches. Am J Epidemiol 156:813-823, 2002
58. Lightwood JM, Glantz SA: Short-term economic and health benefits of smoking cessation: Myocardial infarction and stroke. Circulation 96:1089-1096, 1997
59. United States Public Health Service, Office of the Surgeon General and Center for Chronic Disease Prevention and Health Promotion (U.S.), Office on Smoking and Health: The Health Benefits of Smoking Cessation: A Report of the Surgeon General, Rockville, MD. Washington, DC: U.S. Department of Health and Human Services Public Health Service Centers for Disease Control Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health, 1990, pp xxxiii, 628
60. Ebbert JO, Yang P, Vachon CM, et al: Lung cancer risk reduction after smoking cessation: Observations from a prospective cohort of women. J Clin Oncol 21:921-926, 2003
61. Pohlabeln H, Jockel KH, Muller KM: The relation between various histological types of lung cancer and the number of years since cessation of smoking. Lung Cancer 18:223-229, 1997
62. Eide GE, Heuch I: Attributable fractions: Fundamental concepts and their visualization. Stat Methods Med Res 10:159-193, 2001
63. Benichou J: A review of adjusted estimators of attributable risk. Stat Methods Med Res 10:195-216, 2001
64. Land M, Vogel C, Gefeller O: Partitioning methods for multifactorial risk attribution. Stat Methods Med Res 10:217-230, 2001
65. Repace JL: The problem of passive smoking. Bull N Y Acad Med 57:936-946, 1981
66. United States Office on Smoking and Health and United States Office of the Assistant Secretary for Health and Surgeon General: The Health Consequences of Involuntary Smoking: A Report of the Surgeon General, 1986, Rockville, MD. Washington, DC, U.S. Department of Health and Human Services Public Health Service Centers for Disease Control Center for Health Promotion and Education Office on Smoking and Health, 1986
67. Kawachi I, Pearce NE, Jackson RT: Deaths from lung cancer and ischaemic heart disease due to passive smoking in New Zealand. N Z Med J 102:337-340, 1989
68. Dobson AJ, Alexander HM, Heller RF, et al: Passive smoking and the risk of heart attack or coronary death. Med J Aust 154:793-797, 1991
69. Glantz SA, Parmley WW: Passive smoking and heart disease. Epidemiology, physiology, and biochemistry. Circulation 83:1-12, 1991
70. California Environmental Protection Agency: Office of Environmental Health Hazard Assessment and National Cancer Institute (U.S.), Health Effects of Exposure to Environmental Tobacco Smoke: The report of the California Environmental Protection Agency. NIH publication no. 99-4645. Bethesda, MD, U.S. Dept. of Health and Human Services Public Health Service National Institutes of Health National Cancer Institute, 1999, pp xviii, 15, 430
71. Department of Health UK: Report of the Scientific Committee on Tobacco and Health. London, The Stationary Office, 1998
72. National Health and Medical Research Council, The Health Effects of Passive Smoking: A Scientific Information Paper. Canberra, Australia, National Health and Medical Research Council of Australia, 1997
73. Committee on Passive Smoking, Board on Environmental Studies and Toxicology, and National Research Council, Environmental Tobacco Smoke: Measuring Exposures and Assessing Health Effects. Washington, DC, National Academy Press, 1986
74. Law MR, Morris JK, Wald NJ: Environmental tobacco smoke exposure and ischaemic heart disease: An evaluation of the evidence. BMJ 315:973-980, 1997
75. Howard G, Thun MJ: Why is environmental tobacco smoke more strongly associated with coronary heart disease than expected? A review of potential biases and experimental data. Environ Health Perspect 107(suppl 6):853-858, 1999
76. Kawachi I, Colditz GA: Invited commentary: Confounding, measurement error, and publication bias in studies of passive smoking. Am J Epidemiol 144:909-915, 1996
77. Smith CJ, Fischer TH, Sears SB: Environmental tobacco smoke, cardiovascular disease, and the nonlinear dose-response hypothesis. Toxicol Sci 54:462-472, 2000
78. Moskowitz WB, Schwartz PF, Schieken RM: Childhood passive smoking, race, and coronary artery disease risk: The MCV Twin Study. Medical College of Virginia. Arch Pediatr Adolesc Med 153:446-453, 1999
79. Kawachi I, Colditz GA, Speizer FE, et al: A prospective study of passive smoking and coronary heart disease. Circulation 95:2374-2379, 1997
80. Kawachi I, Colditz GA: Workplace exposure to passive smoking and risk of cardiovascular disease: Summary of epidemiologic studies. Environ Health Perspect 107(suppl 6):847-851, 1999
81. Burghuber OC, Puzengruber C, Sinzinger H, et al: Platelet sensitivity to prostacyclin in smokers and non-smokers. Chest 90:34-38, 1986
82. Otsuka R, Watanabe H, Hirata K, et al: Acute effects of passive smoking on the coronary circulation in healthy young adults. JAMA 286:436-441, 2001
83. He Y, Lam TH, Li LS, et al: Passive smoking at work as a risk factor for coronary heart disease in Chinese women who have never smoked. BMJ 308:380-384, 1994
84. Sarget R, Shepard R, Glantz S: Immediate reduction in acute myocardial infarction after the implementation of a comprehensive smokefree ordinance, in Annual Scientific Sessions of the American College of Cardiology, March 30-April 2, 2003 Chicago, IL: 2003
85. Kupersmith J, Holmes-Rouner M, Hogan A, et al: Cost-effectiveness analysis in heart disease, Part I: General principles. Prog Cardiovasc Dis 37:161-184, 1994
86. Gold MR: Cost-effectiveness in health and medicine. New York, Oxford University Press, 1996, pp xxiii, 425
87. Weinstein M, Zeckhauser R: Critical ratios and efficient allocation. J Publ Econ 2:147-157, 1973
88. Johansson P: Evaluating health risks: An economic approach. New York, Cambridge University Press, 1995, p 190
89. Laska EM, Meisner M, Siegal C, et al: Ratio-based and net benefit-based approaches to health care resource allocation: Proofs of optimality and equivalence. Health Econ 8:171-174, 1999
90. Kupersmith J, Holmes-Rouner M, Hogan A, et al: Cost-effectiveness analysis in heart disease, Part II: Preventive therapies. Prog Cardiovasc Dis 37:243-271, 1995
91. Kupersmith J, Holmes-Rouner M, Hogan A, et al: Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias. Prog Cardiovasc Dis 37:307-346, 1995
92. Tengs TO, Adams ME, Pliskin JS, et al: Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 15:369-390, 1995
93. Zerbe R, Dively D: Benefit-cost analysis in theory and practice. New York, HarperCollins College Publishers, 1994, p 557
94. Ritvo PG, Irvine MJ, Lindsay EA, et al: A critical review of research related to family physician-assisted smoking cessation interventions. Cancer Prev Control 1:289-303, 1997
95. Burns DM: Reducing tobacco use: What works in the population? J Dent Educ 66:1051-1060, 2002
96. Brownson RC, Eriksen MP, Davis RM, et al: Environmental tobacco smoke: Health effects and policies to reduce exposure. Annu Rev Public Health 18:163-185, 1997
97. Fichtenberg CM, Glantz SA: Effect of smoke-free workplaces on smoking behaviour: Systematic review. BMJ 325:188, 2002
98. Moskowitz JM, Lin Z, Hudes ES: The impact of workplace smoking ordinances in California on smoking cessation. Am J Public Health 90:757-761, 2000
99. Longo DR, Johnson JC, Kruse RL, et al: A prospective investigation of the impact of smoking bans on tobacco cessation and relapse. Tob Control 10:267-272, 2001
100. Office of Air and Radiation: Indoor Air Division, The Costs and Benefits of Smoking Restrictions: An Assessment of the Smoke-Free Environment Act of 1993. Washington, DC, United States Environmental Protection Agency, 1994
101. Parrott S, Godfrey C, Raw M: Costs of employee smoking in the workplace in Scotland. Tob Control 9:187-192, 2000
102. Bartosch WJ, Pope GC: Economic effect of restaurant smoking restrictions on restaurant business in Massachusetts, 1992 to 1998. Tob Control 11 (suppl 2):ii38-ii42, 2001
103. Cremieux PY, Ouellette P: Actual and perceived impacts of tobacco regulation on restaurants and firms. Tob Control 10:33-37, 2001
104. Glantz SA, Smith LR: The effect of ordinances requiring smoke-free restaurants and bars on revenues: A follow-up. Am J Public Health 87:1687-1693, 1997
105. Glantz SA, Charlesworth A: Tourism and hotel revenues before and after passage of smoke-free restaurant ordinances. JAMA 281:1911-1918, 1999
106. Wakefield M, Siahpush M, Scollo M, et al: The effect of a smoke-free law on restaurant business in South Australia. Aust N Z J Public Health 26:375-382, 2002
107. Brownson RC, Hopkins DP, Wakefield MA: Effects of smoking restrictions in the workplace. Annu Rev Public Health 23:333-348, 2002
108. Siegel M: The effectiveness of state-level tobacco control interventions: A review of program implementation and behavioral outcomes. Annu Rev Public Health 23:45-71, 2002
109. Siegel M, Mowry PD, Pechecek TP, et al: Trends in adult cigarette smoking in California compared with the rest of the United States, 1978-1994. Am J Public Health 90:372-379, 2000
110. Pierce JP, Gilpin EA, Emery SL, et al: Has the California tobacco control program reduced smoking? JAMA 280:893-899, 1998
111. Fichtenberg CM, Glantz SA: Association of the California Tobacco Control Program with declines in cigarette consumption and mortality from heart disease. N Engl J Med 343:1772-1777, 2000
112. Gilpin EA, Pierce JP: The California Tobacco Control Program and potential harm reduction through reduced cigarette consumption in continuing smokers. Nicotine Tob Res 4(suppl 2):S157-S166, 2002
113. Decline in cigarette consumption following implementation of a comprehensive tobacco prevention and education program - Oregon, 1996-1998. MMWR Morb Mortal Wkly Rep 48:140-143, 1999
114. Biener L, Harris JE, Hamilton W: Impact of the Massachusetts tobacco control programme: Population based trend analysis. BMJ 321:351-354, 2000
115. Manley MW, Pierce JP, Gilpin EA, et al: Impact of the American Stop Smoking Intervention Study on cigarette consumption. Tob Control 6(suppl 2):S12-S16, 1997
116. Luke DA, Stamatakis KA, Brownson RC: State youth-access tobacco control policies and youth smoking behavior in the United States. Am J Prev Med 19:180-187, 2000
117. DiFranza JR, Peck RM, Radechi TE, et al: What is the potential cost-effectiveness of enforcing a prohibition on the sale of tobacco to minors? Prev Med 32:168-174, 2001
118. Costs of smoking among active duty U.S. Air Force personnel - United States, 1997. MMWR Morb Mortal Wkly Rep 49:441-445, 2000
119. Mendez D, Warner KE, Courant PN: Has smoking cessation ceased? Expected trends in the prevalence of smoking in the United States. Am J Epidemiol 148:249-258, 1998
120. Pierce JP, Gilpin E: How long will today's new adolescent smoker be addicted to cigarettes? Am J Public Health 86:253-256, 1996
121. D'Onofrio CN, Moskowitz JM, Braverman MT: Curtailing tobacco use among youth: Evaluation of project 4-health. Health Educ Behav 29:656-682, 2002
122. Livingood WC, Woodhouse CD, Sayre JJ, et al: Impact study of tobacco possession law enforcement in Florida. Health Educ Behav 28:733-748, 2001
123. Stead LF, Lancaster T: Interventions for preventing tobacco sales to minors. Cochrane Database Syst Rev, 1, 2002:CD 001497
124. Siegel M, Biener L, Rigotti NA: The effect of local tobacco sales laws on adolescent smoking initiation. Prev Med 29:334-342, 1999
125. Sowden A, Arblaster L, Stead L: Community interventions for preventing smoking in young people Cochrane Database Syst Rev. 2003; (1): CD 001291
126. Friend K, Levy DT: Reductions in smoking prevalence and cigarette consumption associated with mass-media campaigns. Health Educ Res 17:85-98, 2002
127. Fichtenberg CM, Glantz SA: Youth access interventions do not affect youth smoking. Pediatrics 109:1088-1092, 2002
128. Difranza JR: Youth access: The baby and the bath water. Tob Control 9:120-121, 2000
129. DiFranza JR: Is it time to abandon youth access programmes? Tob Control 11:282-284, 2002
130. Lantz PM, Jacobson PD, Warner KE, et al: Investing in youth tobacco control: A review of smoking prevention and control strategies. Tob Control 9:47-63, 2000
131. Elixhauser A: The costs of smoking and the cost effectiveness of smoking-cessation programs. J Public Health Policy 11:218-237, 1990
132. Warnecke RB, Langenberg P, Wong SC, et al: The second Chicago televised smoking cessation program: A 24-month follow-up. Am J Public Health 82:835-840, 1992
133. Secker-Walker R, Ginch W, Platt S, et al: Community interventions for reducing smoking among adults Cochrane. Database Syst Rev. 2002; (4): CD 001293
134. Paul CL, Sanson-Fisher RW: Experts' agreement on the relative effectiveness of 29 smoking reduction strategies. Prev Med 25:517-526, 1996
135. Sellers DE, Crawford SL, Bullock K, et al: Understanding the variability in the effectiveness of community heart health programs: A meta-analysis. Soc Sci Med 44:1325-1339, 1997
136. Ebrahim S, Smith GD: Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ 314:1666-1674, 1997
137. Farrelly MC, Healton CG, Davis KC, et al: Getting to the truth: Evaluating national tobacco countermarketing campaigns. Am J Public Health 92:901-907, 2002
138. Goldman LK, Glantz SA: Evaluation of antismoking advertising campaigns. JAMA 279:772-777, 1998
139. Pechmann C, Reibling ET: Anti-smoking advertising campaigns targeting youth: Case studies from USA and Canada. Tob Control 9(suppl 2):1118-1131, 2000
140. Sly DF, Trapido E, Ray S: Evidence of the dose effects of an antitobacco counteradvertising campaign. Prev Med 35:511-518, 2002
141. Secker-Walker RH, Worden JK, Holland RR, et al: A mass media programme to prevent smoking among adolescents: Costs and cost effectiveness. Tob Control 6:207-212, 1997
142. Ratcliffe J, Cairns J, Platt S: Cost effectiveness of a mass media-led anti-smoking campaign in Scotland. Tob Control 6:104-110, 1997
143. Stevens W, Thorogood M, Kayikki S: Cost-effectiveness of a community anti-smoking campaign targeted at a high risk group in London. Health Promot Int 17:43-50, 2002
144. Thomas R: School based programmes for preventing smoking (Cochrane Review). Cochrane Library, 1, 2003
145. Wang LY, Crossett LS, Lowry R, et al: Cost-effectiveness of a school-based tobacco-use prevention program. Arch Pediatr Adolesc Med 155:1043-1050, 2001
146. Ketola E, Sipila R, Makela M: Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors. Ann Med 32:239-251, 2000
147. Salkeld G, Phongsavan P, Oldenburg B, et al: The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy 41:105-119, 1997
148. Emmons KM, Linnan LA, Shadel WG, et al: The Working Healthy Project: A worksite health-promotion trial targeting physical activity, diet, and smoking. J Occup Environ Med 41:545-555, 1999
149. Warner KE, Smith RJ, Smith DG, et al: Health and economic implications of a work-site smoking-cessation program: A simulation analysis. J Occup Environ Med 38:981-992, 1996
150. Ringen K, Anderson N, McAfee T, et al: Smoking cessation in a blue-collar population: Results from an evidence-based pilot program. Am J Ind Med 42:367-377, 2002
151. Fiore M, Bailey WC, Cohen SJ, et al: Treating Tobacco Use and Dependence Clinical Practice Guideline. Rockville, MD, U.S. Department of Health and Human Services, Public Health Services, 2000
152. Erfurt JC, Foote A, Heirich MA: Worksite wellness programs: Incremental comparison of screening and referral alone, health education, follow-up counseling, and plant organization. Am J Health Promot 5:438-448, 1991
153. Eriksen MP, Gottlieb NH: A review of the health impact of smoking control at the workplace. Am J Health Promot 13:83-104, 1998
154. Cohen DR, Fowler GH: Economic implications of smoking cessation therapies: A review of economic appraisals. Pharmacoeconomics 4:331-344, 1993
155. Mudde AN, de Vries H, Strecher VJ: Cost-effectiveness of smoking cessation modalities: Comparing apples with oranges? Prev Med 25:708-716, 1996
156. Warner KE: Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharmacoeconomics 11:538-549, 1997
157. Friend K, Levy DT: Smoking treatment interventions and policies to promote their use: A critical review. Nicotine Tob Res 3:299-310, 2001
158. Brown AD, Garber AM: Cost effectiveness of coronary heart disease prevention strategies in adults. Pharmacoeconomics 14:27-48, 1998
159. Silagy C, Stead L: Physician advice for smoking cessation Cochrane Database Syst Rev. 2001;(2): CD 0001165
160. Lancaster T, Stead L: Individual behavioural counselling for smoking cessation Cochrane Database Syst Rev. 2002;(3):CD001292
161. Stead L, Lancaster T, Perera R: Telephone counselling for smoking cessation Cochrane Database Syst Rev. 2003;(1):CD 002850
162. Stead LF, Lancaster T: Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2002;(3):CD 001007
163. Hughes JR, Stead LF, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2002;(1):CD 000031
164. Silagy C, Lancaster T, Stead L, et al: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2002;(4):CD 000146
165. Woolacott NF, Jones L, Forbes CA, et al: The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: A systematic review and economic evaluation. Health Technol Assess 6:1-245, 2002
166. Keeler TE, Hu TW, Keith A, et al: The benefits of switching smoking cessation drugs to over-thecounter status. Health Econ 11:389-402, 2002
167. Pierce JP, Gilpin EA: Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 288:1260-1264, 2002
168. Franzon M, Gustavsson G, Korberly BH, eds. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation: Discussion. JAMA 288:3208-3210, 2002
169. Kristein MM: How much can business expect to profit from smoking cessation? Prev Med 12:358-381, 1983
170. Oster G, Huse DM, Delea TE, et al: Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. JAMA 256:1315-1318, 1986
171. Cummings SR, Rubin SM, Oster G: The cost-effectiveness of counseling smokers to quit. JAMA 261:75-79, 1989
172. Cromwell J, Bartosch WJ, Fiore MC, et al: Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation: Agency for Health Care Policy and Research. JAMA 278:1759-1766, 1997
173. Wasley MA, McNagny SE, Phillips VL, et al: The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med 26:264-270, 1997
174. Fiscella K, Franks P: Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA 275:1247-1251, 1996
175. Song F, Raftery J, Aveyard P, et al: Cost-effectiveness of pharmacological interventions for smoking cessation: A literature review and a decision analytic analysis. Med Decis Making 22(Suppl):S26-S37, 2002
176. Croghan IT, Offord KP, Evans RW, et al: Cost-effectiveness of treating nicotine dependence: The Mayo Clinic experience. Mayo Clin Proc 72:917-924, 1997
177. Tran MT, Holford DA, Kennedy DT, et al: Modeling the cost-effectiveness of a smoking-cessation program in a community pharmacy practice. Pharmacotherapy 22:1623-1631, 2002
178. Kennedy DT, Small RE: Development and implementation of a smoking cessation clinic in community pharmacy practice. J Am Pharm Assoc (Wash) 42:83-92, 2002
179. Kennedy DT, et al: Results of a smoking cessation clinic in community pharmacy practice. J Am Pharm Assoc (Wash) 42:51-56, 2002
180. Wilhelmsson C, Vedin A, Wilhelmsen L: Cost-benefit aspects of post-myocardial infarction intervention. Acta Med Scand Suppl 651:317-321, 1981
181. Wilson K, Gibson N, William A, et al: Effect of smoking cessation on mortality after myocardial infarction: Meta-analysis of cohort studies. Arch Intern Med 160:939-944, 2000
182. Krumholz HM, Cohen BJ, Tsevat J, et al: Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 22:1697-1702, 1993
183. Goldstein MG, Niaura R: Methods to enhance smoking cessation after myocardial infarction. Med Clin North Am 84:63-80, 2000 viii
184. Shinton R: Lifelong exposures and the potential for stroke prevention: The contribution of cigarette smoking, exercise, and body fat. J Epidemiol Community Health 51:138-143, 1997
185. Straus SE, Majumdar SR, McAlister FA: New evidence for stroke prevention: Scientific review. JAMA 288:1388-1395, 2002
186. Hankey GJ, Warlow CP: Treatment and secondary prevention of stroke: Evidence, costs, and effects on individuals and populations. Lancet 354:1457-1463, 1999
187. Suskin N, Sheth T, Negassa A, et al: Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol 37:1677-1682, 2001
188. Lightwood J, Fleischmann KE, Glantz SA: Smoking cessation in heart failure: It is never too late. J Am Coll Cardiol 37:1683-1684, 2001
189. Rigotti NA, Munafo MR, Murphy MF, et al: Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2003;(1):CD 001837
190. Meenan RT, Stevens VJ, Hornbrook MC, et al: Cost-effectiveness of a hospital-based smoking cessation intervention. Med Care 36:670-678, 1998
191. Moller A, Villebro N, Pedersen T: Interventions for preoperative smoking cessation. Cochrane Database Syst Rev. 2001;(4):CD 002294
192. Fiore M: United States. Smoking Cessation Guideline Panel, and Centers for Disease Control and Prevention (U.S.), smoking cessation. Clinical practice guideline no. 18. AHCPR publication no. 96-0692. Rockville, MD, U.S. Dept. of Health and Human Services Public Health Service Agency for Health Care Policy and Research Centers for Disease Control and Prevention, 1996, pp viii, 125
193. Buck DJ, Richmond RL, Mendelsohn CP: Cost-effectiveness analysis of a family physician delivered smoking cessation program. Prev Med 31:641-648, 2000
194. Curry SJ, Grothaus LC, McAfee T, et al: Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med 339:673-679, 1998
195. Halpern MT, Khan ZM, Young TL, et al: Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs. Am J Health Syst Pharm 57:1421-1429, 2000
196. McGhan WF, Smith MD: Pharmacoeconomic analysis of smoking-cessation interventions. Am J Health Syst Pharm 53:45-52, 1996
197. Nielsen K, Fiore MC: Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation. Prev Med 30:209-216, 2000
198. Zhu S, Melcer T, Sun J, et al: Smoking cessation with and without assistance: A population-based analysis. Am J Prev Med 18:305-311, 2000
199. Schauffler HH, McMenamin S, Olson K, et al: Variations in treatment benefits influence smoking cessation: Results of a randomised controlled trial. Tob Control 10:175-180, 2001
200. Manley MW, Griffen T, Foldes SS, et al: The role of health plans in tobacco control. Annu Rev Public Health 24:247-266, 2003
201. Next Generation California Tobacco Control Alliance: Available: http://www.tobaccofreealliance.org/. Accessed 2003
202. State Tobacco Education and Prevention Partnership (STEPP): Available: http://www.cdphe.state. co.us/pp//tobacco/tobaccohom.asp. Accessed: 2003
203. Hodgson TA: Cigarette smoking and lifetime medical expenditures. Milbank Q 70:81-125, 1992
204. Daviglus ML, Liu K, Greenland P, et al: Benefit of a favorable cardiovascular risk-factor profile in middle age with respect to Medicare costs. N Engl J Med 339:1122-1129, 1998
205. Schauffler HH, D'Agostino RB, Kannel WB: Risk for cardiovascular disease in the elderly and associated Medicare costs: The Framingham Study. Am J Prev Med 9:146-154, 1993
206. Levy DT, Chaloupka F, Gitchell J, et al: The use of simulation models for the surveillance, justification and understanding of tobacco control policies. Health Care Manag Sci 5:113-120, 2002
207. McAnulty J, Hopkins DD, Grant-Worley JA, et al: A comparison of alternative systems for measuring smoking-attributable deaths in Oregon, USA. Tob Control 3:115-119, 1994
208. Pronk NP, Goodman MJ, O'Connor PJ, et al: Relationship between modifiable health risks and short-term health care charges. JAMA 282:2235-2239, 1999
209. Edington DW, Yen LT, Witting P: The financial impact of changes in personal health practices. J Occup Environ Med 39:1037-1046, 1997
210. Feingold E: Health care reform - more than cost containment and universal access. Am J Public Health 84:727-728, 1994
211. Yen LT, Edington DW, Witting P: Associations between health risk appraisal scores and employee medical claims costs in a manufacturing company. Am J Health Promot 6:46-64, 1991
212. Pelletier KR: A review and analysis of the health and cost-effective outcome studies of comprehensive health promotion and disease prevention programs at the worksite: 1991-1993 update. Am J Health Promot 8:50-62, 1991
213. Haynes G, Dunnagan T: Comparing changes in health risk factors and medical costs over time. Am J Health Promot 17:112-121, 2002
214. Fichtenberg C, Glantz S: Controlling tobacco use: Discussion and reply. N Engl J Med 344:1797-1798, 2001
215. Capewell S, Morrison CE, McMurray JJ: Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 81:380-386, 1975
216. Hunink MG, Goldman L, Tosteson AN, et al: The recent decline in mortality from coronary heart disease, 1980-1990: The effect of secular trends in risk factors and treatment. JAMA 277:535-542, 1997
217. Moore M, Hughes J: The health care consequences of smoking. Washington, DC, National Bureau of Economic Research, 2000